Report cover image

Migraine Therapeutic Market

Publisher Coherent Market Insights
Published Jul 31, 2025
Length 165 Pages
SKU # CMI20302729

Description

Migraine is a neurological disorder often described as intense pulsing or throbbing pain in one area of the head. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. Migraines are a type of headache that tend to cause other signs and symptoms, too, such as nausea and vision problems. There’s no cure for migraines yet, but medicines can help prevent or stop them, or keep signs and symptoms from getting worse.

Market Dynamics

Increase in prevalence of migraine, increase in demand for safe and effective treatment, increase in awareness about migraine and its treatment options, and rise in research and development across the world are major factors expected to propel the growth of the global migraine therapeutic market during the forecast period. For instance, migraine is a serious and common neurological condition with a serious impact on quality of life. In 2020, migraine has been ranked by WHO as the most prevalent neurological condition causing the highest loss of years due to disability.

In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.

Key features of the study
  • This report provides in-depth analysis of the global migraine therapeutic market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global migraine therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., Novartis International AG, Merck & Co. Inc., GlaxoSmithKline PLC, Eli Lilly and Company, AstraZeneca PLC, Amgen Inc., Allergan Inc., Bausch Health Companies Inc., and Teva Pharmaceutical Industries Ltd., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global migraine therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global migraine therapeutic market.
Market Segmentation
  • Global Migraine Therapeutic Market, By Therapeutics
  • Pain-relieving Medications
  • Preventive Medications
  • Global Migraine Therapeutic Market, By Route of Administration
  • Oral and Nasal
  • Injection
  • Global Migraine Therapeutic Market, By Geography
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
  • Company Profiles
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co. Inc.
  • GlaxoSmithKline PLC
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Amgen Inc.
  • Allergan Inc.
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

165 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Therapeutics
Market Snapshot, By Route of Administration
Market Snapshot, By Geography
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Increase in prevalence of migraine around the world
Adverse effects of drugs and increasing undiagnosed cases
Increase in demand for safe and effective treatment
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
4. Global Migraine Therapeutic Market, By Therapeutics, 2020-2032, (USD Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 – 2032
Segment Trends
Pain-relieving Medications
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Preventive Medications
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
5. Global Migraine Therapeutic Market, By Route of Administration, 2020-2032, (USD Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 – 2032
Segment Trends
Oral and Nasal
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Injection
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
6. Global Migraine Therapeutic Market, By Geography, 2020-2032, (USD Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 – 2032
Segment Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
Country
U.S.
Canada
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
Country
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
Country
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
Country
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
Country
South Africa
North Africa
Central Africa
7. Competitive Landscape
Pfizer Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis International AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co. Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
GlaxoSmithKline PLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca PLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Amgen Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Allergan Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bausch Health Companies Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Teva Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Analyst Views
8. Section
Research Methodology
About us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us